<th id="y8vvx"></th>
<b id="y8vvx"></b>

<u id="y8vvx"><rt id="y8vvx"></rt></u>
<nobr id="y8vvx"></nobr>

<b id="y8vvx"><rt id="y8vvx"><menuitem id="y8vvx"></menuitem></rt></b>

搜索

159-2642-3062

服務熱線(工作日:9:00-17:30)

武漢科斯坦生物科技有限公司

熱搜詞:燕窩酸,不飽和脂肪酸,神經酰胺,花青素,黃酮,皂苷

Wuhan Chemstan Biotechnology Co., Ltd.

武漢科斯坦生物科技有限公司

代謝組學

科研服務

抗體/蛋白

地       址:武漢市東湖新技術開發區高新大道666號,武漢

                 國家生物產業基地B、C、D區研發樓C1棟
產品銷售:15926423062
技術服務:18971263062                                             
E - mail :
info@chemstan.com       
郵       編:430075

化合物單體

科斯坦生物(Chemstan)所有產品和服務僅用于科學研究,不為任何個人或者非科研性質的用途提供產品和服務。

Copyright @ 武漢科斯坦生物科技有限公司.All rights reserved

網站建設:中企動力武漢鄂ICP備19006850號-1

>
>
>
Research Grade Rituximab( 利妥昔單抗 )
瀏覽量:
產品名稱:

Research Grade Rituximab( 利妥昔單抗 )

NO.
001
貨號:
CSD00089
中文名稱
利妥昔單抗
英文名詞
Research Grade Rituximab
CAS號
174722-31-7
產品貨號:
CSD00089
貨期:
現貨
價格與訂購:
2480.00
數量
-
+
庫存:
10
沒有此類產品
產品信息
如何訂購
貨號(Catalog No.)icon
CSD00089
通用名INNicon
Rituximab
純度(Purity)icon
>95%
濃度( Concentration)icon
1mg/ml
Formulationicon
PBS buffer PH7.5
Sourceicon
CHO cells
內毒素(Endotoxin level)icon
Please contact with the lab for this information.
產品描述(Description)icon
Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light and heavy-chain variable region sequences and human constant region sequences 6, Label. It was originally approved by the U.S. FDA in 1997 as a single agent to treat patients with B-cell Non-Hodgkin's Lymphoma (NHL) 8, however, has now been approved for a variety of conditions Label. On November 28, 2018, the US FDA approved Truxima, the first biosimilar to Rituxan (Rituximab) 7.Rituximab is a monoclonal antibody that targets the CD20 antigen, which is expressed on the surface of pre-B and mature B-lymphocytes 1, 2, 3, Label. After binding to CD20, rituximab mediates B-cell lysis (or breakdown). The possible mechanisms of cell lysis include complement dependent cytotoxicity (CDC) and antibody dependent cell-mediated cytotoxicity (ADCC) Label.
別名(Alternative names)icon
IDEC-C2B8
靶點;物種(Specificity target name;species)icon
MS4A1[Homo sapiens]
活性研究(體外/體內研究)(Activity in vitro)icon
Complement-dependent cytotoxicity(CDC), complement-dependent cellular cytotoxicity(CDCC), antibody-dependent cytotoxicity (ADCC) as well as the induction of apoptosis have been claimed to be responsible for the efficacy of rituximab. Rituximab can induce death of malignant B cell lines in vitro. The strength of this effect varies considerably between target cell lines. Changes that have been identified in response to rituximab in vitro include inhibition of p38 mitogen-activated protein kinase, NF-κB, extracellular signal-regulated kinase 1/2 (ERK 1/2) and AKT antiapoptotic survival pathways. Rituximab is highly efficient at mediating CMC(complement dependent cytotoxicity) of various B cell lines as well as fresh malignant B cell samples. CD20-binding capacity of rituximab is dose-dependent.
種類(Species)icon
Chimeric
受體鑒定(Receptor identification)icon
IgG1-kappa
分子量(MV)icon
148000.00 Da
CASicon
174722-31-7
存儲條件(Storage)icon
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
Store at +4°C short term (1-2 weeks).
Store at -20 °C 12 months.
Store at -80°C long term.
Noteicon
For research use only .
未找到相應參數組,請于后臺屬性模板中添加
暫未實現,敬請期待
暫未實現,敬請期待
下一篇
国产对白激情二区_在线无码不卡_777色_亚洲黄色在线视频
<th id="y8vvx"></th>
<b id="y8vvx"></b>

<u id="y8vvx"><rt id="y8vvx"></rt></u>
<nobr id="y8vvx"></nobr>

<b id="y8vvx"><rt id="y8vvx"><menuitem id="y8vvx"></menuitem></rt></b>